Brief Title
Ketohexokinase Isoforms in Endometrial Cancer.
Official Title
Prognostic Evaluations of Ketohexokinase Isoforms in Endometrial Cancer
Brief Summary
Our preliminary analysis with clinical database suggested that, in patients with type I endometrial cancer, high ketohexokinase-expressing group have lower survival probabilities than low ketohexokinase-expressing group. To understand the importance of ketohexokinase expression and isoform switch during the development of type I endometrial cancer, we propose a series of in vitro experiments and clinical examinations in this project.
Study Type
Observational [Patient Registry]
Primary Outcome
The role of ketohexokinase isoforms in the overall survival of endometrial cancer.
Secondary Outcome
Correlation of ketohexokinase isoforms with the other prognostic risk factors
Condition
Endometrial Cancer
Intervention
ketohexokinase
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Diagnostic Test
Estimated Enrollment
220
Start Date
April 11, 2019
Completion Date
December 31, 2024
Primary Completion Date
December 31, 2024
Eligibility Criteria
Inclusion Criteria: - >20 years - Women with endometrial cancer who are about to be admitted to hospital for gynecological staging. - Women who have undergone gynecological staging surgery for endometrial cancer in the past. Exclusion Criteria: - Women with endometrial cancer who receive preoperative chemotherapy or radiation therapy.
Gender
Female
Ages
20 Years - N/A
Accepts Healthy Volunteers
No
Contacts
, +886289667000, [email protected]
Location Countries
Taiwan
Location Countries
Taiwan
Administrative Informations
NCT ID
NCT03931265
Organization ID
108009-F
Responsible Party
Principal Investigator
Study Sponsor
Far Eastern Memorial Hospital
Collaborators
Gynecologic Oncology Group
Study Sponsor
, ,
Verification Date
May 2020